The makers of a popular blood pressure medication who settled class actions alleging that they violated antitrust laws have been cleared of claims that they caused $21 million in damages to one of their largest customers.
Kaiser Foundation Health Plan Inc. had sued Abbott Laboratories and Geneva Pharmaceuticals Inc. for allegedly bilking the managed health care company out of $7 million in potential savings on the purchase of Hytrin, which also relieves the symptoms of enlarged prostate glands. The suit sought triple those damages, plus attorney fees.
